Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action

Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action.

In a preliminary study in healthy subjects, the investigators determined the pharmacokinetic and pharmacodynamic of enteric-coated acetylsalicylic acid (ASA) (Adiro 100 mg, Bayer), and the variability (coefficient of variation), accuracy and precision of a novel biomarker of ASA action, i.e., quantification of the extent of COX-1 acetylation at serine-529, using a stable isotope dilution liquid chromatography multiple reaction monitoring/mass spectrometry (LC-MS) technique.

Now, the investigators will perform a clinical study in individuals undergoing Colorectal cancer (CRC) to validate the hypothesis that that low-dose ASA given once daily is acting primarily by selectively acetylating platelet COX-1 and suppressing its activity throughout the 24-hour dosing interval. In contrast, it is expected that the inhibitory effect on extra-platelet sources of COX-1 will be short-lasting, if any, affecting only partially COX-1, and this effect will be completely reversed at 24 hours after dosing. This is an important point which will strengthen the platelet hypothesis underpinning the apparent adequacy of a 24-hour dosing interval of ASA administration for the anticancer effect detected in cardiovascular trials.

These patients will be stratified into individuals with adenomas/carcinomas (20 to 30%) and patients without clinically detected adenomas/carcinomas (about 70 to 80%).

Study Overview

• Status: Unknown
• Conditions: Colorectal Cancer
• Intervention / Treatment: Drug: Acetylsalicylic acid; Procedure: Screening colonoscopy

• Study Type: Interventional
• Enrollment (Anticipated): 40
• Phase: Phase 3

Contacts and Locations

Study Locations

• Spain
  • Zaragoza, Spain, 50009
    • Hospital Clinico Universitario Lozano Blesa
    • Contact: Angel Lanas Arbeloa, Physician; Phone Number: +34 976 765786; Email: alanas@unizar.es
    • Principal Investigator: Angel Lanas Arbeloa, Physician

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 69 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Men and women, aged ≥ 18 and ≤ 69.

2. Patients should have an indication for screening colonoscopy

   1. First degree relative of patient with CRC.
   2. Personal history of adenomas.
   3. People older than 50 and FOBT positive
3. Routine hematological and biochemical parameters within the normal range.

Exclusion Criteria:

1. Allergy to ASA or other NSAIDs.
2. Previous use of ASA, NSAIDS, antiplatelet agents, corticosteroids or misoprostol in the previous 15 days and/or anticipated need for these drugs during the study period.
3. Peptic ulcer history or any other gastrointestinal disease that could be considered a contraindication for ASA use without the concomitant use of a proton-pump inhibitor.
4. Subjects with coagulation disorder or serious comorbid condition.
5. Malignancies, excluding CRC, diagnosed in the previous 5 years
6. Cigarette smoking, history of drug or alcohol abuse
7. Pregnant women or breast feeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1; Group 1, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at from 6-7 h after the last dose of ASA.	Drug: Acetylsalicylic acid; One tablet of Adiro 100 mg will be administered daily for 7 days.; Other Names: ASA; Adiro 100; Procedure: Screening colonoscopy
Experimental: Group 2; Group 2, individuals will be treated with ASA for 1 week; then blood and tissue samples (during the screening colonoscopy) will be collected at 24 hours after the last dose.	Drug: Acetylsalicylic acid; One tablet of Adiro 100 mg will be administered daily for 7 days.; Other Names: ASA; Adiro 100; Procedure: Screening colonoscopy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of the degree of COX-1 acetylation by ASA administered for 1 week.	It will be performed in platelets versus biopsies of the recto-colonic tissues.	7 hours after the 7th daily dose (group 1) and 24 hours after the 7th daily dose (group 2)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes from baseline in different biomarkers.	It will be used a combining technique of liquid chromatography with mass spectrometry (LC-MS/MS) to quantify the level of acetylation of COX-1 in circulating platelets in subjects treated with ASA. Parameters of the composite measure: haemochrome, AST, ALT, gamma-GT, alkaline phosphatase (AP), total bilirubin, total protein, glucose, creatinine, N, Na, K, Ca.; urine analysis: pH, protein, albumin, glucose, RBC, bilirubin, nitrites, leucocytes and sediment.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)
Changes from baseline in eicosanoid generation in vivo by measuring urinary metabolites derived from COXs.	It will be performed by ultra-performance liquid chromatography tandem mass spectrometry-mass spectrometry (UPLC/MS/MS).	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)
Changes in baseline platelet COX-1	By using human whole blood assay (serum TXB2) ex vivo	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)
Change from baseline in plasma proteins of markers of angiogenesis.	In blood sample by using an antibody array kit and Sphingosine-1 Phosphate (S1P) by immunoassay.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)
Assessment of ASA plasma levels.	Will be performed whole blood aggregation test.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)
Changes from baseline of proteomic profile of selected angiogenesis factors, ie VEGF, FGF2, TGFbeta, EGF, PDGF, MMP, angiogenin, and angiogenesis inhibitors, ie endostatin, PF4, thrombospondin 1, alpha-macroglobulin, PAI 1 and angiostatin.	It will be done in isolated platelets by using an antibody array kit and Sphingosine-1 Phosphate (S1P) by immunoassay.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)
Change from baseline in eicosanoid biosynthesis and protein expression of markers of growth and progression of colorectal cancer (such as COX-2, NF-Kb and PI3K/Akt/mTOR pathway).	It will be done in normal tissues or pathological recto-colonic tissues.	pre-drug on day 0 and after the 7th daily dose (6 hours for Group 1 and 24 hours for Group 2)

Collaborators and Investigators

• Sponsor: Aragon Institute of Health Sciences
• Collaborators: G. d'Annunzio University; Catholic University, Italy
• Investigators: Principal Investigator: Angel Lanas Arbeloa, Physician, Digestive disease service of Hospital Clinico Lozano Blesa

Study record dates

Study Major Dates

• Study Start: May 1, 2014
• Primary Completion (Anticipated): May 1, 2015

Study Registration Dates

• First Submitted: April 25, 2014
• First Submitted That Met QC Criteria: April 28, 2014
• First Posted (Estimate): April 29, 2014

Study Record Updates

• Last Update Posted (Estimate): May 5, 2014
• Last Update Submitted That Met QC Criteria: May 2, 2014
• Last Verified: May 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Colorectal Neoplasms; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Antipyretics; Aspirin
• Other Study ID Numbers: D-13-01; 2013-004269-15 (EudraCT Number)